Wound Healing After Intratumoral EBC-46 Injection: What Phase I Data Reveals

When a compound destroys tumour tissue by design, the question of what happens next — how the body heals the resulting wound — becomes a critical clinical endpoint. Phase I human trial data for tigilanol tiglate has provided the first systematic evidence of the wound healing trajectory following intratumoral EBC-46 injection in human patients, and the results are proving to be one of the compound's most encouraging features.

The Wound Formation Phase: Days 1–7

Immediately following injection, tigilanol tiglate triggers haemorrhagic necrosis of the tumour mass. In the Phase I dose-escalation study, patients treated with cutaneous and subcutaneous lesions experienced visible tumour breakdown within 24 hours, progressing to a well-demarcated eschar (scab) formation by day 3 to 5. The wound margin was typically clean, with necrosis confined to the tumour boundary and minimal damage to surrounding healthy tissue.[1]

Importantly, the acute inflammatory phase — characterised by erythema, oedema, and localised pain — was self-limiting. Most patients reported peak discomfort within the first 48 hours, managed with standard over-the-counter analgesics. No patients required opioid pain management for the injection site alone, a finding that distinguishes EBC-46 from more invasive tumour ablation procedures.

The Granulation Phase: Weeks 2–4

As the necrotic tumour tissue sloughed or was debrided, granulation tissue appeared at the wound base. This highly vascularised tissue, rich in fibroblasts and new capillaries, is the hallmark of normal secondary intention healing. Clinical photographs from the trial demonstrate robust granulation in the majority of treated wounds by week 2, with progressive wound contraction reducing the defect size by approximately 40–60% before re-epithelialisation began.

The quality of granulation tissue observed after EBC-46 treatment is notable. Unlike wounds created by surgical excision or thermal ablation, which can produce excessive scar tissue, the EBC-46 wound bed appeared to support orderly collagen deposition. Researchers have hypothesised that the neutrophil-to-macrophage transition triggered by EBC-46 may promote a reparative rather than fibrotic healing programme.[2]

Re-Epithelialisation and Cosmetic Outcomes

Complete wound closure was achieved in the majority of treated lesions within 4 to 6 weeks, depending on the size and depth of the original tumour. Superficial lesions (less than 1 cm diameter) healed within 3 weeks in several cases, while larger or deeper tumours required up to 8 weeks for full re-epithelialisation.

The cosmetic outcomes reported in the Phase I trial were described as acceptable to good by both investigators and patients. While the treated sites were visible as areas of depigmentation or mild scarring, the results compared favourably to surgical excision of similar-sized lesions, particularly in anatomically sensitive areas such as the face, neck, and hands where surgical options may require complex reconstructive procedures.

Comparison with Veterinary Wound Healing Data

The human wound healing timeline is broadly consistent with the extensive veterinary data accumulated during the Stelfonta registration programme. In canine mast cell tumours treated with tigilanol tiglate, De Ridder and colleagues reported complete wound healing in a median of 4.4 weeks, with 97% of treated sites achieving full closure without surgical intervention.[3]

This cross-species consistency provides additional confidence in the predictability of the wound healing process and suggests that the underlying mechanism — PKC-mediated inflammation followed by orderly tissue repair — is conserved across mammalian species.

Implications for Treatment Planning

The predictable wound healing pattern has important implications for clinical trial design and, eventually, for clinical practice. Unlike surgical excision, which requires pre-operative planning, anaesthesia, and potentially complex wound closure, EBC-46 injection creates a wound that heals by secondary intention without the need for sutures, skin grafts, or flap reconstruction. For patients with superficial tumours in visible or cosmetically sensitive locations, this non-surgical approach may offer a meaningful quality-of-life advantage.

The ongoing Phase II trials are collecting more detailed wound healing data, including standardised photographic documentation and patient-reported outcome measures, that will further define the expected healing trajectory across different tumour types and anatomic sites.

References

[1] Redd et al. Phase I study of intratumoral tigilanol tiglate in patients with solid tumours. EBioMedicine (2019)

[2] Moses RL et al. Wound repair mechanisms following PKC-mediated tumour ablation. J Pathol (2016)

[3] De Ridder TR et al. Randomized controlled clinical study of tigilanol tiglate in canine mast cell tumours. Vet Comp Oncol (2021)